Search This Blog

Tuesday, January 24, 2023

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas

 

  • Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas

  • Acquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolio

  • Addition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)